ARMOR2: A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer

ID Number 14-0093

Principal Investigator(s)
Matthew Galsky

Department(s) or Division(s)
Hematology and Medical Oncology

Description

The purpose of this trial is to confirm the safest dose of galeterone, to find out how galeterone moves through the body, to see if there is any evidence that galeterone is effective at treating prostate cancer in men who have failed treatment, and to gather more information about possible side effects.


Tumors can grow for many reasons. Prostate cancer tumor growth is, in part, related to something called the androgen receptor. The androgen receptor is a protein found in prostate cancer cells. When the androgen receptor attaches to the male sex hormone, testosterone, it sends a signal that makes the tumor cells grow and increases the levels of prostate specific antigen (PSA).


While there are many ways of blocking testosterone such as castration or with drugs like LupronĀ®), at some stage prostate cancer becomes resistant. This is in part due to the production of testosterone by the prostate cancer itself, and also by the adrenal glands. In addition, at times it is believed that the cancer becomes much more responsive to very low levels of testosterone.



Contact Information
(212) 824-7309

Recruiting Patients: Yes